Sponsors ECM2022

At BMS, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We commit to scientific excellence and investment in biopharmaceutical research and development to provide innovative, high-quality medicines that address the unmet medical needs of patients. We apply scientific rigor to produce clinical and economic benefit through medicines that improve patients’ lives. We strive to make information about our commercialized medicines widely and readily available. We actively seek to improve access to care, advocate for policies that promote health equity, and help underserved patients access and afford the medicines they need. We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues.

Xylyx Bio is a New York-based biotechnology company that specializes in sourcing, characterizing, and developing tissue-specific extracellular matrix (ECM) biomaterials that are compatible with pre-clinical tissue models. Our IN MATRICO® Fibrosis Platform leverages a physiologically-relevant approach for anti-fibrotic drug development that incorporates minimally-processed, human-derived, normal and diseased cell culture environments for more predictive analysis. With deep scientific expertise, our team of scientists is leading the paradigm shift toward offering more biologically-relevant platforms that enable researchers to gain insight into the relationship between the cellular microenvironment and complex diseases as well as increased confidence in evaluating therapeutic candidates within clinically-relevant assays.

Amunix is an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop therapies for patients. Amunix’s approach is to expand the therapeutic index of T cell engagers (TCEs) and cytokine therapies, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose limiting toxicity. Amunix utilizes its protease-releasable masking technology to create conditionally active TCEs and cytokines preferentially activated in tumors as compared to healthy tissues.

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Ectica Technologies is a proud sponsor of the Extracellular Matrix Pharmacology Congress. Ectica offers pre-formed and characterized ex-vivo human stromal models for screening-compatible tumor-stroma interaction studies. Ectica 3DProSeed^TM StromaLine collection includes patient-derived cancer associated fibroblasts (CAFs) for subsequent co-cultures with adenocarcinoma cells, a stromal model of the human bone marrow vascular niche and others. The StromaLine is available in 96-well imaging plate format and is developed using synthetic, animal-free hydrogel materials.

FibroFind is a rapidly developing Newcastle-based biomedical sciences company that has a deep understanding of the biology of fibrosis and has employed this knowledge to design bespoke biological assays with human tissues that can determine if a novel drug is able to prevent fibrosis and halt disease. The business focus for FibroFind is their proprietary human fibrosis bioassays that provide a pre-clinical service for pharmaceutical and biotechnology companies developing medicines that target fibrosis. This business model has proved to be highly valued by its growing client base which currently stands at 90 companies based in the USA, Asia and Europe. Despite only beginning trading 3 years ago, FibroFind has already contributed towards new medicines entering into ongoing clinical trials.

Galecto, Inc. is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin family generally) and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and expected to be evaluated in a phase 2 trial for the treatment of NSCLC in combination with an anti-PD1/-L1 product.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. With our proprietary FIND-IO™ platform, we discover new targets and structural components of immune cells and understand their impact in disease to develop immunomedicines. Our focus is to bring new treatments to patients not responding to current therapies, patients who progress despite treatment and patients with diseases not adequately addressed by available therapies.

Nordic Bioscience specializes in precision medicine using extracellular matrix Protein Fingerprint biomarkers. All chronic diseases are characterized by an imbalance of the extracellular matrix with elevated levels of either protein formation or degradation. Nordic Biosciences specialized extracellular matrix Protein Fingerprint technology measures the tissue imbalance seen in all chronic diseases.

Nordic Bioscience improve patient care by combining the Protein Fingerprint technology with their expertise in preclinical and clinical research. They assist the improvement of drug development by better selection of patients and reduction of trial length and size.

Nordic Bioscience’s approach is highly scientific, and they are proud to publish their results frequently in leading journals worldwide

Pliant is a clinical-stage biopharmaceutical company leading development of new treatments for fibrotic diseases and focused on changing the treatment landscape. By understanding the molecular drivers of fibrotic diseases, we hope to unlock potentially safer, and more effective therapies. Pliant’s focus is on using tissue-specific integrin targets to block TGF-β, a key driver of fibrosis. Our extensive expertise in integrin and fibrosis biology has our sights set on creating groundbreaking new therapies for fibrosis-related diseases.

Redx is a UK based small molecule biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases. We have two compounds in clinical development, a rich pipeline of pre-clinical projects, and large Pharma collaborations. We’re utilising our unique knowledge of both cancer and fibrosis to target the tumour stroma in highly fibrotic tumours as a method of enhancing the efficacy of current cancer treatments.

Roche Diagnostics is a division of Roche. We develop and integrate diagnostic solutions that address the challenges of today and anticipate the needs of tomorrow. In more than 100 countries, we offer the industry’s most comprehensive in vitro diagnostics solutions, covering molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, and laboratory automation and IT, and decision support solutions.

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

3Helix strives to empower collagen for diagnosing and treating human fibrotic conditions. Our Collagen Hybridizing Peptides (CHPs) can target and bind to denatured/remodeling collagen based on structural recognition. The triple-helical structural recognition enables CHPs to detect the entire collagen alpha chains across all collagen types, regardless of species

Gelatex Technologies is a Techstars-backed materials company from Estonia that is revolutionizing nanofiber production. Gelatex has patented a novel high-capacity
solution-spinning method and device for nanofiber manufacturing to innovate cultured meat, tissue engineering, and many other industries. The material comes in rolls, is easily scalable, and is up to 90% cheaper than current nanofibrous materials.

MedChemExpress is a global life-science manufacturing company, headquartered in NJ/USA. MCE supplies a wide range of high-quality research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs, and natural compounds to most of the renowned research institutes, laboratories, biotech companies, and pharmaceutical companies across the world since 2008.

Optics11 Life offers powerful table-top nanoindenters to measure the mechanical properties of complex, irregular biomaterials such as single cells, tissues, hydrogels, and organoids.

At ECM2022, we present our Pavone instrument, designed to enable an automated high throughput analysis of the mechanical properties of any soft and living materials.

EACR 2022 – Innovative Cancer Science: Translating Biology to Medicine

EACR 2022 is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.

Date and location: Seville, Spain | 20 – 23 June 2022

Deadlines:

• Bursary application deadline: 07 March 2022
• Abstract submission deadline: 07 March 2022
• Registration deadline: 20 April 2022

Looking to stay up to date on the latest cell biology research? Science News by STEMCELL Technologies can help. Our website and weekly newsletters keep scientists current with the latest peer-reviewed research, as well as industry and policy news. Check out Extracellular Matrix News for the latest research on the ECM’s role in immune regulation, tumors, development, wound repair, and more.

Cancer Drug Resistance is a gold open access and quarterly published journal committed to the rapid publication of high quality, peer-reviewed, original research. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes involved include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.

Copper 2022  is a  biennial conference and  is the premier venue for bringing together clinicians, scientists, and trainees focusing on various aspects of copper biology, chemistry, and therapeutics. The meeting provides a unique opportunity to identify clinical needs, discuss new findings, and rapidly disseminate ideas and methodologies, all prerequisites for translating fundamental discoveries into therapeutic interventions. Topics to be covered include the role of copper in inherited disease, neurological disorders, microbial infectious disease, and cancer and cellular differentiation and proliferation

Cancers (ISSN 2072-6694) is a peer-reviewed, open access journal of oncology, published semimonthly online by MDPI. It is indexed by the Science Citation Index Expanded (impact factor of 6.639 for 2021 and is ranked Q1: Oncology), Scopus, PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases. It publishes high-quality articles including basic, translational, and clinical studies on all tumor types. The article types include Research Papers, Reviews, Editorials, Communications, etc.